Antibody Therapies Vs. Omicron: Vir Stands Up But Regeneron And Lilly Fail

Regeneron Pledges Update By Early 2022

 
• By Andrew McConaghie
  
Covid testing lab
The results suggest the most widely used antibody therapies are be 'inactive' against Omicron. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D